XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Summary of Revenues Disaggregated by Product Classification and Reportable Segment (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation Of Revenue [Line Items]        
Total revenue $ 52,483 $ 24,854 $ 104,614 $ 73,963
Product Sales [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 15,667 13,919 45,251 40,227
Royalties [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 34,153 8,795 52,347 26,738
Research, Development and Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2,663 2,140 7,016 6,998
Operating Segments [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 52,483 24,854 104,614 73,963
Operating Segments [Member] | Medical Device [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 46,014 17,528 84,739 52,889
Operating Segments [Member] | Medical Device [Member] | Product Sales [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 9,299 6,741 25,593 19,970
Operating Segments [Member] | Medical Device [Member] | Royalties [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 8,220 7,771 23,702 23,015
Operating Segments [Member] | Medical Device [Member] | License Fees [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 25,933 1,024 28,645 3,723
Operating Segments [Member] | Medical Device [Member] | Research, Development and Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2,562 1,992 6,799 6,181
Operating Segments [Member] | In Vitro Diagnostics [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 6,469 7,326 19,875 21,074
Operating Segments [Member] | In Vitro Diagnostics [Member] | Product Sales [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 6,368 7,178 19,658 20,257
Operating Segments [Member] | In Vitro Diagnostics [Member] | Research, Development and Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue $ 101 $ 148 $ 217 $ 817